New drug hopes to keep stage III lung cancer at bay after Chemo-Radiation
NCT ID NCT07204548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called ivonescimab can help prevent lung cancer from growing back after standard chemoradiation. It involves 63 adults with stage III non-small cell lung cancer that cannot be removed by surgery. Participants will receive ivonescimab infusions for one year, and researchers will track how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivonescimab (also called AK112), a drug given by IV after chemoradiation
What this could lead to
If it works, this could offer a new option to delay cancer progression in patients with stage III lung cancer who cannot have surgery.
What could go wrong
This is a small, early-phase trial with only 63 participants and no comparison group. The drug may not improve outcomes and could cause side effects like immune-related inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Li-Kun Chen
Guangzhou, Guangzhou, 510006, China